Higher toxicities may have been anticipated by PACCE investigators.
The triple therapy arm of this trial is directly analogous to the triple therapy arm of the PACCE trial (i.
The corrected release reads: AMGEN DISCONTINUES VECTIBIX[TM] TREATMENT IN PACCE TRIAL EVALUATING VECTIBIX[TM] AS PART OF TRIPLE COMBINATION REGIMEN
Amgen (NASDAQ:AMGN) today announced that it has discontinued Vectibix[TM] (panitumumab) treatment in the PACCE trial evaluating the addition of Vectibix to standard chemotherapy and Avastin[R] (bevacizumab) for the treatment of first-line metastatic colorectal cancer (mCRC).
For this reason, we have decided to discontinue Vectibix treatment in the PACCE trial while we complete additional analyses of these preliminary results.
Amgen has notified the FDA and study investigators that patients who are still receiving treatment in the PACCE study should discontinue Vectibix treatment.
Amgen Press Release: Amgen discontinues Vectibix(TM) treatment in PACCE
trial evaluating Vectibix(TM) as part of triple combination regimen.
The clinical trial called the PACCE
(Panitumumab Advanced Colorectal Cancer Evaluation) study is a randomized, multi-center, open label study with endpoints of progression-free survival, overall survival and response rate.
Adopting a law and economics perspective, Pacces (law and finance, Erasmus U.